Expression of MiR-335 and its target metalloproteinase genes: clinical significance in breast cancer. (4th May 2022)

• Record Type: Journal Article
• Authors: Ramadan, Amal; Hashim, Maha; M. Hassan, Naglaa; Swellam, Menha
• Is Part Of: Archives of physiology and biochemistry. Volume 128:Number 3(2022)
• Page Start: 569
• Page End: 575
• Publication Date: 2022-05-04
• Subjects: Breast cancer -- miR-335 -- MMP2 -- MMP9 -- diagnosis -- clinicopathological characteristics; Physiology -- Periodicals; Biochemistry -- Periodicals; Biophysics -- Periodicals; Biochemistry; Physiology; 571
• DOI: 10.1080/13813455.2019.1703004
• Languages: English
• ISSNs: 1381-3455

Abstract

Abstract: Background: Early diagnosis of breast cancer decreases mortality rate; therefore, novel diagnostic methods are urgently required. In this study, authors aimed to investigate the role of serum-derived miR-335 in breast cancer, and the expression of matrix metalloproteinase-2 (MMP2) and matrix metalloproteinase-9 (MMP9) and evaluating their feasibility and clinical utility as biomarkers for the early detection of breast cancer. Materials and methods: Blood samples were collected from a total of 210 individuals who were enrolled in this study. The participants were divided into newly diagnosed breast cancer patients ( n = 115), patients with benign breast lesions ( n =55) and healthy individuals as control group ( n =40). The expression profile of miR-335, MMP2 and MMP9 were determined using quantitative polymerase chain reaction (qPCR). Results: MiR 335 expression level was down-regulated in primary breast cancer group as compared to benign breast group and healthy individuals with 98% and 94.9% sensitivity and specificity, respectively. MMP2 and MMP9 showed significantly higher expression levels in breast cancer group as compared to both benign and healthy group and reporting 92.7% and 93% sensitivity, respectively. The relations between investigated markers and pathologic types, staging, grading, and lymph node involvement were significant with these factors. Expression level of miR-335 was decreased with increased MMP2 and MMP9 at significant level. Conclusion: MiR-335, MMP2, and MMP9 can be used as diagnostic markers in breast cancer.